Novartis AG (NVS) Shares Bought by Camden National Bank
Camden National Bank increased its holdings in Novartis AG (NYSE:NVS) by 3.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 57,411 shares of the company’s stock after purchasing an additional 1,873 shares during the period. Camden National Bank’s holdings in Novartis AG were worth $4,928,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of NVS. Geode Capital Management LLC lifted its holdings in Novartis AG by 19.8% in the 1st quarter. Geode Capital Management LLC now owns 18,918 shares of the company’s stock worth $1,405,000 after purchasing an additional 3,125 shares in the last quarter. Lowe Brockenbrough & Co. Inc. lifted its holdings in Novartis AG by 1.9% in the 1st quarter. Lowe Brockenbrough & Co. Inc. now owns 20,754 shares of the company’s stock worth $1,541,000 after purchasing an additional 380 shares in the last quarter. Farmers National Bank lifted its holdings in Novartis AG by 6.0% in the 1st quarter. Farmers National Bank now owns 5,974 shares of the company’s stock worth $472,000 after purchasing an additional 339 shares in the last quarter. Community Trust & Investment Co. lifted its holdings in Novartis AG by 2.1% in the 1st quarter. Community Trust & Investment Co. now owns 10,543 shares of the company’s stock worth $783,000 after purchasing an additional 218 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Novartis AG by 489.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,159 shares of the company’s stock worth $160,000 after purchasing an additional 1,793 shares in the last quarter. 10.74% of the stock is currently owned by institutional investors.
A number of research firms recently commented on NVS. J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a report on Tuesday, October 31st. Zacks Investment Research raised Novartis AG from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Barclays PLC cut Novartis AG from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Finally, Leerink Swann boosted their price target on Novartis AG from $89.00 to $91.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $85.32.
Novartis AG (NVS) traded up $0.20 during trading hours on Thursday, reaching $84.48. The company’s stock had a trading volume of 1,540,300 shares, compared to its average volume of 2,325,532. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. Novartis AG has a 1-year low of $66.93 and a 1-year high of $86.90. The company has a market cap of $199,372.34, a P/E ratio of 17.74, a price-to-earnings-growth ratio of 2.69 and a beta of 0.72.
Novartis AG (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.04. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The business had revenue of $12.41 billion for the quarter, compared to the consensus estimate of $12.21 billion. During the same quarter in the previous year, the company posted $1.23 EPS. The company’s revenue was up 2.4% compared to the same quarter last year. equities research analysts expect that Novartis AG will post 4.75 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/23/novartis-ag-nvs-shares-bought-by-camden-national-bank.html.
Novartis AG Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.